Perrigo Company plc $PRGO Holdings Lifted by Janney Montgomery Scott LLC

Janney Montgomery Scott LLC lifted its stake in Perrigo Company plc (NYSE:PRGO - Free Report) by 18.3% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 85,339 shares of the company's stock after purchasing an additional 13,213 shares during the quarter. Janney Montgomery Scott LLC owned 0.06% of Perrigo worth $2,280,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Sound Income Strategies LLC boosted its position in shares of Perrigo by 6.2% in the 2nd quarter. Sound Income Strategies LLC now owns 528,964 shares of the company's stock valued at $14,134,000 after purchasing an additional 30,888 shares during the period. Paragon Capital Management Ltd boosted its position in Perrigo by 8.9% during the 2nd quarter. Paragon Capital Management Ltd now owns 7,923 shares of the company's stock worth $212,000 after acquiring an additional 650 shares during the period. Novem Group lifted its holdings in shares of Perrigo by 2.5% during the 2nd quarter. Novem Group now owns 110,770 shares of the company's stock valued at $2,960,000 after buying an additional 2,692 shares during the last quarter. Public Employees Retirement System of Ohio lifted its holdings in shares of Perrigo by 1.4% during the 2nd quarter. Public Employees Retirement System of Ohio now owns 42,290 shares of the company's stock valued at $1,130,000 after buying an additional 564 shares during the last quarter. Finally, GAMMA Investing LLC lifted its holdings in shares of Perrigo by 32.7% during the 2nd quarter. GAMMA Investing LLC now owns 4,891 shares of the company's stock valued at $131,000 after buying an additional 1,206 shares during the last quarter. Institutional investors and hedge funds own 95.91% of the company's stock.

Perrigo Stock Performance

PRGO opened at $21.55 on Friday. The stock has a market cap of $2.96 billion, a PE ratio of -37.15 and a beta of 0.43. The company has a current ratio of 2.32, a quick ratio of 1.24 and a debt-to-equity ratio of 0.81. Perrigo Company plc has a 1 year low of $20.51 and a 1 year high of $30.93. The stock's 50 day simple moving average is $22.80 and its 200-day simple moving average is $25.25.

Perrigo (NYSE:PRGO - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The company reported $0.57 EPS for the quarter, missing the consensus estimate of $0.59 by ($0.02). The company had revenue of $1.06 billion during the quarter, compared to analyst estimates of $1.08 billion. Perrigo had a negative net margin of 1.86% and a positive return on equity of 9.09%. Perrigo's quarterly revenue was down .9% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.53 EPS. Sell-side analysts forecast that Perrigo Company plc will post 2.56 EPS for the current year.

Perrigo Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 16th. Investors of record on Friday, August 29th were paid a $0.29 dividend. The ex-dividend date of this dividend was Friday, August 29th. This represents a $1.16 annualized dividend and a yield of 5.4%. Perrigo's payout ratio is currently -200.00%.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on PRGO. JPMorgan Chase & Co. reduced their price target on Perrigo from $38.00 to $35.00 and set an "overweight" rating for the company in a report on Thursday, August 7th. Wall Street Zen upgraded Perrigo from a "hold" rating to a "buy" rating in a report on Sunday, September 28th. Canaccord Genuity Group reduced their price target on Perrigo from $42.00 to $40.00 and set a "buy" rating for the company in a report on Thursday, August 7th. Finally, Weiss Ratings restated a "sell (d)" rating on shares of Perrigo in a report on Wednesday. Two equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, Perrigo presently has an average rating of "Hold" and a consensus target price of $34.00.

Insider Buying and Selling

In related news, Director Geoffrey M. Parker purchased 4,375 shares of the firm's stock in a transaction that occurred on Monday, August 18th. The shares were acquired at an average price of $22.97 per share, with a total value of $100,493.75. Following the purchase, the director directly owned 33,287 shares in the company, valued at $764,602.39. This represents a 15.13% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO Eduardo Guarita Bezerra purchased 3,000 shares of the firm's stock in a transaction that occurred on Monday, August 18th. The stock was bought at an average cost of $22.74 per share, for a total transaction of $68,220.00. Following the purchase, the chief financial officer owned 48,949 shares in the company, valued at $1,113,100.26. This represents a 6.53% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders acquired 10,118 shares of company stock worth $232,699 in the last quarter. Corporate insiders own 0.70% of the company's stock.

Perrigo Company Profile

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.